EXACT Sciences (EXAS) and Eloxx Pharmaceuticals (ELOX) Critical Comparison

Eloxx Pharmaceuticals (NASDAQ: EXAS) and EXACT Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent recommendations and price targets for Eloxx Pharmaceuticals and EXACT Sciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eloxx Pharmaceuticals 0 0 4 0 3.00
EXACT Sciences 0 2 9 0 2.82

Eloxx Pharmaceuticals presently has a consensus target price of $25.25, suggesting a potential upside of 67.00%. EXACT Sciences has a consensus target price of $66.10, suggesting a potential upside of 32.68%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than EXACT Sciences.


This table compares Eloxx Pharmaceuticals and EXACT Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals N/A -248.30% -162.16%
EXACT Sciences -35.24% -20.10% -12.69%

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and EXACT Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals $80,000.00 6,318.27 -$21.21 million N/A N/A
EXACT Sciences $265.99 million 22.99 -$114.39 million ($0.99) -50.32

Eloxx Pharmaceuticals has higher earnings, but lower revenue than EXACT Sciences.

Institutional and Insider Ownership

87.2% of EXACT Sciences shares are held by institutional investors. 44.0% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of EXACT Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Eloxx Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, EXACT Sciences has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.


Eloxx Pharmaceuticals beats EXACT Sciences on 7 of the 12 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply